Jyong Biotech Ltd. (MENS) fair value analysis
Nasdaq · Updated 2026-10-19
MENS price how computed
Valuation status
No fair-value estimate yetMENS has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MENS yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $1.84
- Sector
- Healthcare
- 12-month range
- $1.46–$60.80
- Market cap
- $137M
- From 52-week high
- -97.0%
- Shares outstanding
- 74.2M
- Rank in Healthcare by quality score
- #296 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Jyong Biotech Ltd. is a healthcare company that focuses on the development and commercialization of biopharmaceutical products. The company operates primarily in Asia, with a presence in multiple markets within the region.
MENS currently ranks #296 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $137M
- Gross margin
- 0.0%
- Debt / equity
- 0.00
- Shares outstanding
- 74.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 39 · neutral
- 50-day average
- $2.11
- 200-day average
- $2.25
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 1 quarters vs consensus
- 0 beat, 1 missed
- Quarter by quarter
- 2025-03 ▼ miss
What our data shows for MENS
- Shares are trading in the lower third of their 12-month price range of $1.46–$60.80.
- The 14-day relative strength index sits at a neutral 39.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MENS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MENS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MENS stock undervalued?
TickrTrends has no fair-value estimate for MENS yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MENS's TickrTrends verdict?
MENS is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MENS compare to other Healthcare stocks?
MENS ranks #296 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MENS overbought or oversold?
MENS's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does MENS usually beat earnings estimates?
Over its last 1 reported quarters MENS beat the consensus estimate 0 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.